Luminex Webinars

Webinar: xMAP® Technology Drives Development of Prostate Cancer Detection Assay

For a startup company striving to deliver diagnostics that improve health care for patients who may have prostate cancer, Luminex’s xMAP® Technology is a critical tool in the assay development process. According to a webinar presentation from Ramy Huber, a research associate at ProteoMediX, the assay multiplexing technology allowed his team to develop an assay that has reduced unnecessary biopsies by more than 50% in clinical studies.

The presentation lasts just 20 minutes and includes many helpful tips for other teams interested in finding out whether multiplexing technology would make a difference for them.

Embed

Discussion